'I was refused service in a cafe because of my face'
The 35-year-old from Birmingham described how visiting an independent coffee shop in London recently "everyone was staring at me, and it was like they'd almost seen a ghost".
"The person serving looked at me and said: 'Oh, we're not serving any more'.
"She turned around and walked off. But clearly, clearly they were still serving."
Amit was born with Neurofibromatosis type 1, a condition that causes non-cancerous tumours to grow along nerves.
But after "learning acceptance" of his facial disfigurement he now shares his motivational story in schools with the aim of helping children "embrace their personalities and celebrate who they are".
Another recent experience of abuse spurred him on to self publish a children's book, Born Different.
"I had a couple of individuals come over to me in a park and ask me what happened to my face, and I thought they were just being curious," he said.
"But actually they started laughing, giggling, saying: 'Oh my God, if I had a face like you I wouldn't even come out my house'."
He said the encounter "really upset" him, "and I thought to myself, I need to do something about this. I need to get this book out. Now is the right time".
"If I had this book when I was a young child, I think it would have helped me."
Amit had his left eye surgically removed at the age of 11, leading to further facial disfigurement as well as abuse and bullying.
In the run up to Halloween one year, a child at school told him "you don't need a Halloween mask, you've got one for life", he recalled.
"That broke me to the point where I did not accept the left hand side of my face," he said.
"For a very, very long time I hid the face, I just was not comfortable showing it to the world at all."
Looking back, he said he had not understood the depth of depression and anxiety he experienced then.
"Other children not wanting to come and sit next to me or hiding behind their parents all had a mental effect on me," he said.
At school, cricket was his passion and it was through playing the game that he eventually made friends.
"Cricket helped me become Amit, that boy who plays cricket, from Amit, the boy who has a funny face," he explained.
But, he said, even as an adult he still experienced "constant staring".
"The pointing, the tapping the friend next to them saying 'have you seen that guy's face', that is also constant," he said.
"But there is kindness out there as well, and that needs highlighting."
It was his wife Piyali who eventually taught him the "art of acceptance," he explained.
"Really that I've got to accept myself before others can accept me," he added.
She also persuaded him to start sharing his story on social media.
"I thought TikTok was all about singing and dancing, and I thought maybe not, but she convinced me.
"I created a video and I said to the world: 'I want to take you all on a journey to help and support and inspire you using my lived experiences.'"
He started his account in early 2023, and has since gone on to gain almost 200,000 followers and millions of likes.
"Me helping people on social media by sharing my story has helped me become more accepting of myself.
"Now I say to the world, this is me, take it or leave it."
At about the same time, he left his job at a law firm to take up motivational speaking full time.
Helping young people felt so much more important, he said.
He is also about to launch a podcast in which he speaks to others who have had similar experiences, including Oliver Bromley who was ejected from a restaurant because staff said he was "scaring the customers".
"We're going to have lots of fun and inspire a lot of people," he said.
"Disability or no disability, visible difference or no visible difference, we all have insecurities, we all have things that we're faced with, and challenges we're faced with.
"I just want to give this narrative to people that if we truly celebrate who we are, accept who we are, fall in love with who we are, then we can be more confident."
Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
'Restaurant ejected me due to my disfigurement'
The secret I'm hiding under my baggy clothes
'You are the modern day Elephant Man'
Amit Ghose TikTok
Nerve Tumours UK
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Common pill you can buy for pennies could ward off Alzheimer's
Omega fatty acids, found in certain fish or taken as a supplement, could potentially help ward off Alzheimer's disease in women, a new study suggests. Researchers found that lipids – fat molecules in the body – are different in women with Alzheimer's and those without. But they stressed that more work was needed to see whether 'shifting the lipid composition can influence the biological trajectory' of the disease. Scientists from Kings College London and Queen Mary University London, examined blood samples taken from 841 people, including 306 people with Alzheimer's; 165 with mild cognitive impairment and 370 healthy people. They discovered that there was a noticeable loss of unsaturated fats, including those that contain omega fatty acids, in the blood of women with Alzheimer's disease compared to healthy women, according to the study, which has been published in the journal Alzheimer's and Dementia: The Journal of the Alzheimer's Association. READ MORE: People urged to put bowl of water on windowsill as heatwave hits Wales READ MORE: Lucy Letby has 'new hope' as barrister prepares to submit appeal file They also noted a steep increase in lipids with saturation – also known as 'unhealthy lipids' – in women with Alzheimer's compared to women without. But there was no difference between these fat molecules between men with, and without, a diagnosis of Alzheimer's – which researchers say could help deepen knowledge about why more women than men are diagnosed with Alzheimer's disease. 'Women are disproportionately impacted by Alzheimer's disease and are more often diagnosed with the disease than men after the age of 80,' said senior author of the study Dr Cristina Legido-Quigley, from King's College London. One of the most surprising things we saw when looking at the different sexes was that there was no difference in these lipids in healthy and cognitively impaired men, but for women this picture was completely different. 'The study reveals that Alzheimer's lipid biology is different between the sexes, opening new avenues for research. Our study suggests that women should make sure they are getting omega fatty acids in their diet – through fatty fish or via supplements. 'However, we need clinical trials to determine if shifting the lipid composition can influence the biological trajectory of Alzheimer's Disease.' Dr Asger Wretlind, first author of the study from King's College London, said: 'Although this still warrants further research, we were able to detect biological differences in lipids between the sexes in a large cohort, and show the importance of lipids containing omegas in the blood, which has not been done before. 'The results are very striking and now we are looking at how early in life this change occurs in women.' Dr Julia Dudley, head of research at Alzheimer's Research UK, which funded the study along with LundbeckFonden, said: 'In the UK, two in three people living with dementia are women. 'This could be linked to living longer, or other risk factors like social isolation, education, or hormonal changes from the menopause being at play. While this study shows that women with Alzheimer's had lower levels of some unsaturated fats compared with men, further work is needed. 'This includes understanding the mechanisms behind this difference and finding out if lifestyle changes, including diet could have a role.' People can consume omega-3 fatty acids by eating fatty fish including salmon, mackerel or sardines, or by taking a supplement. It comes as a separate study found that children who had a diet rich in omega-3 fatty acids may have a reduced risk of short sightedness. The study, published in the British Journal of Ophthalmology, examined data on 1,005 Chinese children aged between six and eight years, including their eye sight and regular surveys about their diet. Overall 28% of children had myopia. Researchers from Hong Kong found that a higher consumption of omega-3 fatty acids was associated with a lower risk of the condition.
Yahoo
3 hours ago
- Yahoo
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
CNN
7 hours ago
- CNN
In break with current CDC recommendations, American Academy of Pediatrics recommends Covid-19 shots for young children
Source: CNN The American Academy of Pediatrics released its updated recommendations for vaccines on Tuesday, including Covid-19 shots for infants and young children – a break from the current US for Centers for Disease Control and Prevention recommendations. 'It differs from recent recommendations of the Advisory Committee on Immunization Practices of the CDC, which was overhauled this year and replaced with individuals who have a history of spreading vaccine misinformation,' the AAP said in a news release. Current CDC recommendations for the Covid-19 vaccine for children ages 6 months to 17 years should be 'based on shared clinical decision-making,' the agency says. The AAP recommendations are more explicit. It says that all children ages 6 through 23 months should receive a Covid-19 vaccine unless they have known allergies to the vaccine or its ingredients. It also recommends a single dose of the vaccine for children ages 2 through 18 years if they are at high risk of Covid-19, residents of long-term care facilities, have never been vaccinated against Covid-19, or live in a household with people who are high risk for Covid-19. It also says that the vaccine should be available for this age group even if they are not in these risk groups. AAP has provided vaccine recommendations and published its own vaccine schedule throughout its nearly century-long history. But it has not traditionally diverged from federal recommendations. Other groups – including the Vaccine Integrity Project, a group of outside public health experts – have also been independently reviewing data on vaccines out of concern for vaccine misinformation and access under current federal health leadership. Tension between AAP and those driving federal health policy has been running high for months, particularly around changes to the Advisory Committee on Immunization Practices, or ACIP. AAP has long been a liaison to ACIP, participating in meeting discussions and analyzing research in workgroups behind the scenes. But AAP chose not to participate in the ACIP meeting in June – the first since health secretary Robert F. Kennedy Jr. dismissed all 17 members of the expert panel, replacing them with seven new ones. Dr. Sean O'Leary, chair of the AAP Committee on Infectious Diseases, said at the time that AAP liaisons to ACIP did not participate in the meeting 'because we view it as illegitimate.' 'What we heard in this meeting was really a false narrative that the current vaccine policies are flawed and that they need fixing,' he said. In August, AAP was one of roughly 30 medical and public health organizations that were formally sidelined from their roles as ACIP liaisons and told by email that they could no longer participate in the committee's crucial workgroups. The email called the liaison members 'special interest groups' that are 'expected to have a 'bias' based on their constituency and/or population they represent.' Vaccine recommendations from ACIP have statutory implications. Under the Affordable Care Act, insurance companies are required to cover vaccines for adults if they've been recommended by ACIP. The committee also votes on whether vaccines should be added to the federal Vaccines for Children program, which provides vaccines to children who would not otherwise be able to afford them. In Tuesday's news release, AAP urged insurance providers to cover the vaccines that are included in their schedule. 'The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children and adolescents,' AAP President Dr. Susan J. Kressly in the said in the news release. 'Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving.' The AAP also issued updated recommendations for RSV and flu vaccines, in addition to more than 10 other vaccines. The US Department of Health and Human Services responded to the AAP's immunization schedule by calling on the agency to 'strengthen conflict-of-interest safeguards and keep its publications free from financial influence.' 'The American people deserve confidence that medical recommendations are based solely on science and public health,' HHS communications director Andrew Nixon wrote in a statement. 'Instead, the AAP is undermining national immunization policymaking with baseless political attacks. Secretary Kennedy has stood firm in his commitment to science, transparency, and restoring public trust. By bypassing the CDC's advisory process and freelancing its own recommendations, while smearing those who demand accountability, the AAP is putting commercial interests ahead of public health and politics above America's children.' In response to HHS' comments, AAP continued to emphasize its commitment to evidence-based recommendations. 'AAP created its vaccine schedule based on the health of children and the evidence showing how vaccines support their immune systems, so they can stay healthy and do all the things we want children to be able to do,' Kressly said in a statement. 'The Academy has been making vaccine recommendations for over 90 years, longer than ACIP has been in existence, and we remain committed to supporting children's access to vaccines,' she said. 'AAP's recommendations are based only in the science, the needs of children, and the care that pediatricians have for the children in every community.' The Vaccine Integrity Project on Tuesday presented data from its independent review of thousands of research papers assessing the safety and effectiveness of Covid-19, flu and RSV vaccines. The evidence it found is 'very consistent' with the latest recommendations from the AAP, said Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota and leader of the new initiative. 'Let me just be clear: We've looked at this very carefully, and there simply is no scientific evidence to support the change that HHS made to the Covid [vaccine] recommendations for pregnant women or for children most at risk for high-risk transmission or severe disease,' Osterholm said. 'Over the last few months, we've seen policy changes by federal officials based on evidence that has been shown as flawed, analytically fraught or flat out wrong. It's vital that providers and the public continue to have vaccine information they can rely on,' he said. Analyses by the Vaccine Integrity Project are ongoing, with more information to be shared in the coming weeks as the US quickly approaches respiratory virus season. Other changes may make access to vaccines difficult in other ways this fall. The US Food and Drug Administration has said it may limit future Covid-19 shots to older people and those who are at high risk for serious infection, and may not renew authorization for Pfizer's Covid-19 vaccine for children younger than 5 years old. CNN's Brenda Goodman, Sarah Owermohle and Meg Tirrell contributed to this report. See Full Web Article
